Axsome Therapeutics | 4:持股变动声明-董事 Coleman Mark
Axsome Therapeutics | 3:首次持股声明-高管 Maizel Ari
Axsome Therapeutics | 4:持股变动声明-董事 Saad Mark E
Axsome Therapeutics | 4:持股变动声明-高管 Jacobson Mark L.
Axsome Therapeutics | 4:持股变动声明-董事 Mahony Susan
Axsome Therapeutics | 4:持股变动声明-董事 Coleman Mark
Axsome Therapeutics | 4:持股变动声明-董事 JEFFS ROGER
Axsome Therapeutics | 4:持股变动声明-董事 Saad Mark E
Axsome Therapeutics | 4:持股变动声明-高管 Jacobson Mark L.
Axsome Therapeutics | 4:持股变动声明-董事 Coleman Mark
Axsome Therapeutics | 4:持股变动声明-高管 Jacobson Mark L.
Axsome Therapeutics | 4:持股变动声明-董事 JEFFS ROGER
Axsome Therapeutics | 4:持股变动声明-董事 JEFFS ROGER
Axsome Therapeutics | 4:持股变动声明-董事 Saad Mark E
Axsome Therapeutics | 4:持股变动声明-高管 Jacobson Mark L.
Axsome Therapeutics | 4:持股变动声明-高管 Pizzie Nick
Axsome Therapeutics | 4:持股变动声明-高管 TABUTEAU HERRIOT
Axsome Therapeutics | 4:持股变动声明-董事 Mahony Susan
Axsome Therapeutics | 4:持股变动声明-高管 Murdock Hunter R.
Axsome Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Fairmount Funds Management LLC(4.9%),Peter Harwin(4.9%)等